CTNM Contineum Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1855175 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.9%
TTM EPS YoY21.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.8%
ROA-28.3%
ROIC (approx.)-37.1%
Asset turnover—
Leverage & solvency
Liabilities / assets4.5%
Debt / equity0.00x
Current ratio31.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $0 |
| R&D expense | $15.98M | $12.70M | $11.65M | $12.76M | $10.99M | $14.06M | $13.71M | $13.02M |
| SG&A expense | $4.98M | $4.73M | $5.26M | $4.36M | $3.94M | $3.84M | $4.40M | $4.03M |
| Operating income | -$20.97M | -$17.43M | -$16.90M | -$17.11M | -$14.93M | -$17.90M | -$18.11M | -$17.05M |
| Interest expense | — | — | — | — | — | — | — | $0 |
| Pretax income | — | — | — | — | — | — | — | -$14.56M |
| Income tax | — | — | — | — | — | — | — | $0 |
| Net income | -$18.70M | -$15.15M | -$14.46M | -$15.16M | -$12.79M | -$16.04M | -$15.99M | -$14.56M |
| EBITDA | -$20.89M | -$17.29M | -$16.82M | -$17.03M | -$14.85M | -$17.82M | -$18.03M | -$16.97M |
| EPS (basic) | -0.49 | -0.40 | -0.39 | — | -0.45 | -0.62 | -0.62 | — |
| EPS (diluted) | -0.49 | -0.40 | -0.39 | — | -0.45 | -0.62 | -0.62 | — |
| Weighted avg. shares (diluted) | 38.39M | 37.47M | 37.34M | — | 28.12M | 25.90M | 25.87M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $75.20M | $14.71M | $20.16M | $75.60M | $42.63M | $20.78M | $22.47M | $21.94M |
| Short-term investments | $169.29M | $221.84M | $226.17M | $187.29M | $139.77M | $154.70M | $168.24M | $182.82M |
| Current assets | $249.74M | $242.58M | $252.96M | $267.92M | $184.93M | $176.84M | $192.13M | $206.39M |
| PP&E, net | $848,000 | $929,000 | $1.06M | $830,000 | $880,000 | $856,000 | $891,000 | $989,000 |
| Total assets | $256.99M | $250.37M | $261.35M | $276.64M | $190.85M | $182.89M | $198.26M | $212.85M |
| Current liabilities | $8.03M | $6.53M | $6.66M | $9.74M | $6.36M | $7.21M | $8.95M | $9.97M |
| Total liabilities | $11.57M | $10.71M | $11.31M | $15.65M | $10.38M | $11.50M | $13.50M | $14.78M |
| Shareholders' equity | $245.42M | $239.66M | $250.04M | $260.99M | $180.47M | $171.39M | $184.77M | $198.07M |
| Cash flow statement | ||||||||
| Operating cash flow | -$11.06M | -$11.50M | -$16.27M | -$13.04M | -$12.20M | -$15.66M | -$14.41M | -$10.20M |
| Capital expenditure | $0 | $6,000 | $312,000 | $42,000 | $98,000 | $44,000 | $47,000 | $166,000 |
| Free cash flow | -$11.06M | -$11.51M | -$16.58M | -$13.08M | -$12.29M | -$15.71M | -$14.46M | -$10.37M |
| Investing cash flow | $50.95M | $4.85M | -$39.31M | -$47.45M | $14.94M | $13.88M | $14.91M | -$9.39M |
| Financing cash flow | $20.59M | $1.20M | $129,000 | $93.47M | $19.11M | $91,000 | $24,000 | $642,000 |
| Depreciation & amortization | $81,000 | $134,000 | $83,000 | $85,000 | $81,000 | $79,000 | $78,000 | $75,000 |
| Stock-based compensation | $4.86M | $3.84M | $3.82M | $2.48M | $2.57M | $2.42M | $2.57M | $2.25M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.